Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Aug;11(8):2940-2945.
doi: 10.21037/tcr-22-426.

Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report

Rui Wu #  1 , Yinghui Ju #  1 , Tengfei Long  1 , Zhuping Su  1 , Gaochao Zhu  1 , Sheng Liu  2
Affiliations
Case Reports

Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report

Rui Wu et al. Transl Cancer Res. 2022 Aug.

Abstract

Background: Programmed cell death protein-1 (PD-1) or its ligand PD-L1 monoclonal antibodies, opening a new era of tumor immunotherapy, and they have significantly improved the overall survival of many patients with advanced solid tumors. However, in addition to its effectiveness, we should also pay attention to its adverse effects. The instructions of the PD-1 inhibitor camrelizumab clearly indicate that reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse reaction; it is common for many immune checkpoint inhibitors (ICIs). Here we describe a case that anlotinib improved RCCEP induced by anti-PD-1 blockade camrelizumab with some focus on further management of this symptoms.

Case description: A 57-year-old man with squamous cell carcinoma of the upper lobe of the left lung, and with mediastinal lymphocyte and liver metastasis, received the fifth cycle of chemotherapy and immunotherapy with camrelizumab (200 mg, every 3 weeks). Four days after treatment with camrelizumab, the patient's face, head, neck, and chest skin had multiple scattered bright red round papules, which were diagnosed as RCCEP. The patient was treated with oral anlotinib (8 mg, once a day). After 5 days of treatment, the symptoms of RCCEP gradually eased, and the patient was discharged.

Conclusions: In conclusion, we have reported a case of RCCEP induced by anti-PD-1 blockade camrelizumab. The patient was given oral anlotinib to relieve the symptoms of RCCEP. Suggesting that anlotinib could be a potential management to reduce the adverse reactions who are treated with camrelizumab. The risk for RCCEP should always be kept in mind during camrelizumab treatment.

Keywords: Camrelizumab; anlotinib; case report; programmed cell death protein-1 (PD-1); reactive cutaneous capillary endothelial proliferation (RCCEP).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-426/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Substantial space-occupying lesions at the bronchial opening of the upper lobe of the left lung. Lobulation can be seen at the edge, and the bronchial opening of the upper lobe of the left lung is narrow and occluded. The lesions were significantly improved on 31 August 2021 (B) compared with 22 June 2021 (A). The yellow arrows indicated the lesions.
Figure 2
Figure 2
RCCEP induced by anti-PD-1 blockade camrelizumab. (A) RCCEP was located on the scalp and trunk of the patient. (B) A rash was under the left eye of the patient, which ruptured and bled. The black arrows indicated the RCCEP. This image is published with the patient consent. RCCEP, reactive cutaneous capillary endothelial proliferation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zhou J, Mao Q, Li Y, et al. Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review. BMC Oral Health 2021;21:559. 10.1186/s12903-021-01901-9 - DOI - PMC - PubMed
    1. Tang B, Chi Z, Chen Y, et al. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. Clin Cancer Res 2020;26:4250-9. 10.1158/1078-0432.CCR-19-3922 - DOI - PubMed
    1. Chen Y, Zhang H, Shi J, et al. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report. Onco Targets Ther 2020;13:12471-6. 10.2147/OTT.S279004 - DOI - PMC - PubMed
    1. Darnell EP, Mooradian MJ, Baruch EN, et al. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep 2020;22:39. 10.1007/s11912-020-0897-9 - DOI - PubMed
    1. Zhang X, Wang M, Shi B. Reactive capillary hemangiomas induced by camrelizumab in a patient with hepatocarcinoma. Int J Dermatol 2021;60:e409-10. 10.1111/ijd.15606 - DOI - PubMed

Publication types